Press releases

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS, has been named executive vice president and...

WASHINGTON, D.C., USA, Nov. 20, 2023 – BD (Becton Dickinson and Company), a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday,...

Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a currency-neutral basis Q4 revenue from base business (which...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.95 per common share, an increase of 4.4% from the previous quarter. The dividend...

New Peripheral Line Draw Solution Delivers First and Only Compatibility with Integrated Catheters, Bringing Elevated Standard of Care to More U.S. Hospitals FRANKLIN LAKES, N.J., Nov. 2, 2023...

Results of the SAFE-DCB Registry support long-term safety and effectiveness for the Lutonix™ DCB in a real-world patient population with femoropopliteal disease.

Company Ranks Top 2 in Healthcare Equipment and Services Industry FRANKLIN LAKES, N.J., Oct. 18, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice president and treasurer will also add head of...

All Used Injection Devices Recycled; Next Stage of Pilot to Expand Regionally, Add Medical Devices FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023 fourth quarter and full year financial results on...

FRANKLIN LAKES, N.J. (Oct. 1, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced Bridget Bagnato has been named president of BD...

Recognition underscores company's commitment to transparency and values FRANKLIN LAKES, N.J., Sept. 19, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following healthcare conferences: 2023 Wells Fargo...

First patient enrollment in ARCH study begins investigation of the safety and effectiveness of the BD Liverty™ Transjugular Intrahepatic Portosystemic Shunt (TIPS) Stent Graft to reduce...

Increased manufacturing capacity combined with an expansion from 69 to 92 eligible countries, is expected to enable delivery of more than 320 million doses through 2030 Previously guaranteed...

Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion...

Single Test on BD MAX™ System Identifies and Differentiates Multiple Respiratory Infectious Diseases from One Sample FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, payable on September 29, 2023 to holders of record on...

Reflects Commitment to Gender Equality and Progress in Advancing ESG Strategy FRANKLIN LAKES, N.J. (July 25, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher,...

BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the...

BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe pumps, patient-controlled analgesia (PCA)...

Company Expands its ESG Focus Areas to Include Advancing Health Equity in Under-Resourced Communities FRANKLIN LAKES, N.J., July 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:...

FRANKLIN LAKES, N.J. (July 13, 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it is one of 200 companies named to U.S....